180 Wealth Advisors LLC Makes New $34,000 Investment in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX)

180 Wealth Advisors LLC bought a new stake in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,000 shares of the company’s stock, valued at approximately $34,000.

Analyst Ratings Changes

Separately, Raymond James upgraded shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, May 22nd.

Eupraxia Pharmaceuticals Price Performance

EPRX stock traded down $0.01 on Thursday, reaching $2.60. The company’s stock had a trading volume of 4,742 shares, compared to its average volume of 18,327. Eupraxia Pharmaceuticals Inc. has a 52 week low of $2.39 and a 52 week high of $5.75. The company has a market capitalization of $70.93 million and a P/E ratio of -2.61. The business has a fifty day simple moving average of $2.63.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.